Author headshot

E. Michael Lewiecki, MD, FACE, FACP

Lewiecki is the director of the New Mexico Clinical Research and Osteoporosis Center and director of Bone Health TeleECHO Clinic, University of New Mexico Health Sciences Center.

Most recent by E. Michael Lewiecki, MD, FACE, FACP

SPONSORED CONTENT
July 19, 2024
3 min read
Save

Osteoporosis treatment equally lowers hip fracture risk for both men and women

Osteoporosis treatment reduces the risk for hip fractures for older men just as well as it does for older women, according to a study published in Journal of Bone and Mineral Research.

SPONSORED CONTENT
March 06, 2024
2 min read
Save

Denosumab use for osteoporosis may also lower risk for diabetes

Adults with osteoporosis who received a full course of denosumab were less likely to develop incident diabetes than those who discontinued denosumab after the initial dose, according to study data published in JAMA Network Open.

SPONSORED CONTENT
November 13, 2023
1 min read
Save

Bone density decreases when stopping, never using menopausal hormone therapy

Postmenopausal women who stopped or never used hormone therapy over a 5-year period experienced a loss in bone density, whereas bone density was maintained for those who continued treatment, researchers reported in Menopause.

SPONSORED CONTENT
August 08, 2023
2 min watch
Save

VIDEO: Virtual community of bone clinicians review cases with Bone Health ECHO

SANTA FE, N.M. — In this video exclusive, E. Michael Lewiecki, MD, FACE, FACP, describes Bone Health ECHO, a virtual community of physicians who review osteoporosis and bone-disease cases together each week via video conferencing.

SPONSORED CONTENT
May 10, 2023
2 min read
Save

High comorbidity burden among men with subsequent osteoporotic fractures

SEATTLE — Among men aged at least 40 years who experienced a fracture, most with subsequent fractures in the next 2 years had cardiometabolic comorbidities and used medications linked to increased fall risk, according to researchers.

SPONSORED CONTENT
December 21, 2022
1 min read
Save

FDA approves abaloparatide for men with osteoporosis at high risk for fracture

The FDA has approved abaloparatide, a parathyroid hormone-related peptide analog, to increase bone mineral density among men with osteoporosis at high risk for fracture, according to an industry press release.

SPONSORED CONTENT
March 18, 2022
2 min read
Save

Alendronate therapy associated with depression, anxiety

Compared with other first-line osteoporosis treatments, alendronate therapy yielded an increased risk for depression and anxiety, according to an analysis of adverse events reports.

SPONSORED CONTENT
February 22, 2021
3 min read
Save

Moderate physical activity may prevent fractures for middle-aged adults

Even moderate levels of leisure-time physical activity in middle age are associated with lower risk for fractures, according to study data published in the Journal of Bone and Mineral Research.